Impact of elexacaftor/tezacaftor/ivacaftor therapy on P2X7R airway epithelial cell expression and inflammasome signalling in cystic fibrosis
Innate Immunity · 2026-11 · 32
DOI: 10.1177/17534259261503719 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innate Immunity, online erschienen am 11.11.2026. Verfasst von Debananda Gogoi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Hauptthemen laut MEDLINE: Cystic Fibrosis, Receptors, Purinergic P2X7, Inflammasomes, Aminophenols. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Background
Purinergic receptor activation via extracellular adenosine-5′-triphosphate (eATP) is involved in the pathogenesis of cystic fibrosis (CF) through P2X7-receptor (P2X7R) mediated NLRP3 (NOD-, LRR-, and pyrin-domain-containing protein 3) inflammasome activation and interleukin-1β (IL-1β) production.
Objectives
The aim of this study was to explore P2X7R expression in nasal (NECs) and airway epithelial cells (AECs) of people with CF (pwCF), and to record the in vivo and in vitro impact of CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI) therapy.
Methods
CFTR and P2X7R expression levels were measured in vivo in CF NECs (n=5) before and after 12 months ETI therapy, or in vitro , in normal (NuLi-1) and CF (CuFi-1, Phe508del/Phe508del genotype) AECs. NLRP3 expression, caspase-1 activity and IL-1β secretion were measured in AECs, and following stimulation with ATP and lipopolysaccharides (LPS).
Results
P2X7R is overexpressed in CF NECs in vivo (p=0.0079), in CF AECs (CuFi-1, Phe508del/Phe508del genotype) in vitro (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- Office of Research and Innovation, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- Cystic Fibrosis Unit, Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland.
ORCID-Profile: Emer P Reeves
Förderung
- Cystic Fibrosis Foundation
Zitieren
APA
Gogoi, D., Baird, R., Yusuf, A., Pietsch, K., Bolger, C., Alghamdi, S., Acquilini, P., DCosta, L., McCabe, O., Gunaratnam, C., Casey, M., & Reeves, E. P. (2026). Impact of elexacaftor/tezacaftor/ivacaftor therapy on P2X7R airway epithelial cell expression and inflammasome signalling in cystic fibrosis. Innate Immunity, 32. https://doi.org/10.1177/17534259261503719
Vancouver
Gogoi D, Baird R, Yusuf A, Pietsch K, Bolger C, Alghamdi S, et al. Impact of elexacaftor/tezacaftor/ivacaftor therapy on P2X7R airway epithelial cell expression and inflammasome signalling in cystic fibrosis. Innate Immunity. 2026;32. doi:10.1177/17534259261503719
BibTeX
@article{Gogoi2026,
author = {Gogoi, Debananda and Baird, Rory and Yusuf, Azeez and Pietsch, Karin and Bolger, Caoimbhe and Alghamdi, Sabrina and Acquilini, Parisa and DCosta, Lorraine and McCabe, Olive and Gunaratnam, Cedric and Casey, Michelle and Reeves, Emer P},
title = {Impact of elexacaftor/tezacaftor/ivacaftor therapy on P2X7R airway epithelial cell expression and inflammasome signalling in cystic fibrosis},
journal = {Innate Immunity},
year = {2026},
volume = {32},
doi = {10.1177/17534259261503719}
}
EUVIMED